SCHEMBL4266953

SCHEMBL4266953

CC(=O)c1ccccc1OCCCCCC(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
ALDH1A1 P00352 4/20 0.64
KDM4E B2RXH2 2/20 0.64
MAPT P10636 6/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
HTT P42858 1/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
HIF1A Q16665 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
NR1I2 O75469 1/20 0.54
CHRM2 P08172 1/20 0.54
CYP3A4 P08684 1/20 0.54
ADRA2A P08913 1/20 0.54
OPRK1 P41145 1/20 0.54
HTR2B P41595 1/20 0.54
SLC6A3 Q01959 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
CNR2 P34972 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145231 1.00 LMNA (0.68) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL2562760 0.94 LMNA (0.68) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL13527398 0.89 LMNA (0.69) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL2555648 0.89 LMNA (0.70) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL2517739 0.87 ALDH1A1 (0.65) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL19717846 0.87 ALDH1A1 (0.65) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL5512491 0.87 ALDH1A1 (0.65) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL5514981 0.85 ALDH1A1 (0.67) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL13545502 0.85 ALDH1A1 (0.61) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL10102738 0.85 LMNA (0.68) LMNASMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046736-B1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2019-06-12 EP disclosed
US-20180334430-A1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2018-11-22 US disclosed
US-9873667-B2 Arylsulfanyl compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES INC. (US) 2018-01-23 US disclosed
US-7951971-B1 Phenoxy carboxylic acid compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-31 US disclosed
US-7951971-B1 Phenoxy carboxylic acid compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-31 US disclosed
US-20090258817-A1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS NOVO NORDISK A/S (DK) 2009-10-15 US disclosed
EP-2046736-A1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS Emisphere Technologies, Inc. (US) 2009-04-15 EP disclosed
WO-2008014430-A1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258817-A1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS ABCB7, ABCB4, PAICS LMNA 753/4885SMN1; SMN2 96/4885ALDH1A1 1627/4885
US-20180334430-A1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS ABCB7, ABCB4, PAICS LMNA 753/4885SMN1; SMN2 96/4885ALDH1A1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.